Kimberly-Clark Corporation (KMB) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2024. Kimberly-Clark Corporation operates three reportable segments: Personal Care, Consumer Tissue, and K-C Professional. The company is currently executing a 2024 Transformation Initiative aimed at reorganizing into three new business segments, optimizing the supply chain, and reducing structural costs, with total anticipated pre-tax costs of approximately $1.5 billion.
Key Financial Metrics
| Metric (in millions, except per share) | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Net Sales | $4,952 | $5,132 | $15,130 | $15,461 |
| Operating Profit | $1,154 | $774 | $2,662 | $1,674 |
| Net Income (Attributable to K-C) | $907 | $587 | $2,098 | $1,255 |
| Diluted EPS | $2.69 | $1.73 | $6.21 | $3.70 |
| Cash Provided by Operations (9M) | $2,417 | $2,327 | ||
| Capital Spending (9M) | ||||
| Total Debt (Sept 30, 2024) | $7,451 ($569 current + $6,882 long-term) | |||
| Cash and Equivalents | $1,111 |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 4% in Q3 and 2% YTD, primarily due to unfavorable currency translation (-3% to -4%) and divestitures. However, organic sales grew 1% in Q3 and 4% YTD, driven by net selling price increases in hyperinflationary economies (notably Argentina).
- Profitability: Operating profit increased 49% in Q3 and 59% YTD. This significant increase is largely attributable to a $566 million pre-tax gain from the sale of the Personal Protective Equipment (PPE) business in Q3 2024, compared to a $74 million gain from the Brazil tissue sale in Q2 2023.
- Impairments: The company recognized a $97 million pre-tax impairment charge in Q3 2024 related to intangible assets (Softex and Thinx brands), compared to $658 million in Q2 2023.
- Transformation Costs: Charges related to the 2024 Transformation Initiative totaled $124 million pre-tax in Q3 and $359 million pre-tax YTD.
Guidance, Outlook, and Risks
- Transformation Outlook: The company expects to complete the transition to the new organizational structure by the end of 2024, with the full initiative concluding by the end of 2026. Total pre-tax savings are projected at $3.0 billion in gross productivity plus $200 million in SG&A savings.
- Capital Allocation: Full-year capital spending is anticipated to be approximately $800 million. The company repurchased 4.2 million shares in Q3 and 5.4 million shares YTD.
- Risks and Contingencies:
- Geopolitical: Operations in Russia (approx. 1-2% of sales) face sanctions, supply chain restrictions, and potential asset impairment risks.
- Transformation Execution: Risks include disruptions to operations, delays in implementation, and failure to realize anticipated cost savings.
- Market Conditions: Exposure to raw material costs, energy prices, and foreign currency fluctuations (specifically in Argentina and Türkiye).
Investor Verification Checklist
- Adjusted Earnings: Verify the "As Adjusted Non-GAAP" metrics (Adjusted Operating Profit of $810M in Q3; Adjusted EPS of $1.83) to understand core operational performance excluding the PPE sale gain and transformation charges.
- Intangible Asset Valuation: Review the assumptions used in the $97M impairment charge for Softex and Thinx to assess the risk of future write-downs.
- Organic Growth Drivers: Confirm the sustainability of organic sales growth driven by pricing in hyperinflationary economies versus volume trends in North America and Developed Markets.
- Transformation Progress: Monitor the burn rate of the $1.5 billion transformation budget and the timeline for realizing the projected $3.2 billion in savings.
- Debt Profile: Note the reduction in total debt from $8.0 billion (Dec 2023) to $7.5 billion (Sept 2024) and the utilization of the $2.0 billion revolving credit facility.